The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Site-specific analysis of extranodal involvement in patients with LBCL treated with CAR-T therapy
Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the impact of extranodal disease at the time of CAR T-cell therapy in patients with large B-cell lymphoma (LBCL). Dr Iacoboni highlights that patients with concomitant nodal and extranodal disease performed more poorly in terms of progression-free survival (PFS), overall survival (OS), and complete response (CR) rates compared to patients with only nodal or only extranodal disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
